Clinical Trials Logo

Chorioretinitis clinical trials

View clinical trials related to Chorioretinitis.

Filter by:

NCT ID: NCT05335746 Recruiting - Vitiligo Clinical Trials

Ocular Changes in Vitiligo Patients on Therapy

Start date: March 10, 2022
Phase:
Study type: Observational

Vitiligo patients on systemic and local therapy may have some ocular adverse effects associated with the disease and its therapy.

NCT ID: NCT05153057 Recruiting - Posterior Uveitis Clinical Trials

Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)

CO-BIRD
Start date: November 2, 2004
Phase:
Study type: Observational

The purpose of this study is twofold: 1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina. Various imaging techniques will be used to assess the effect of the disease on the retina and the choroid. A standardized assessment of the visual function will be performed with visual acuity, visual field and color vision testing. The quality of life of the patients will be evaluated with the VFQ-25 questionnaire. These analyses will help delineating different forms of the disease among its heterogeneous presentations. 2. To identify predisposing factors for the disease. The condition is unique from the immunogenetic standpoint by its association with the HLA-A29 allele, which is the strongest link between an HLA class I antigen and a disease. To date, however, the mechanisms leading to birdshot chorioretinopathy remain unknown. GWAS (Genome Wide association Study) based on DNA of the cohort patients will be performed with the aim to identify other susceptibility genes associated with BCR.

NCT ID: NCT04947592 Recruiting - Fungal Retinitis Clinical Trials

SD-OCT Guided Treatment of Fungal Chorioretinitis

Start date: January 15, 2020
Phase:
Study type: Observational

Fungal Chorioretinitis is a vision threatening condition.The investigators evaluate the efficacy of SD-OCT role in the treatment

NCT ID: NCT04245072 Recruiting - Chorioretinitis Clinical Trials

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

COAST_UAcCNV
Start date: March 27, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to central chorioretinitis.

NCT ID: NCT03753893 Completed - Macular Edema Clinical Trials

Ocular Manifestations in Rheumatic Diseases

Start date: May 1, 2013
Phase:
Study type: Observational

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

NCT ID: NCT02843438 Completed - Clinical trials for Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

BIOLUVE
Start date: January 2010
Phase: N/A
Study type: Interventional

Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful. Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans. The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis. The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

NCT ID: NCT01552044 Completed - Clinical trials for Central Serous Chorioretinitis

Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to evaluate the effect of spironolactone on 16 patients presenting with chronic non-resolutive central serous chorioretinitis (CSCR) and to evaluate whether spironolactone can resolve sub retinal fluid in these patients. CSCR is a major cause of visual loss in the young population. It is characterized by sub retinal fluid under the retina and retinal pigment epithelial detachments. The exact causes of the disease remain unknown but a choroidopathy has been suggested. Moreover, corticotherapy and stress are known risk factors of CSCR. Our preclinical studies have demonstrated that the mineralocorticoid pathway could be involved in the control of choroidal blood flow. The investigators propose to evaluate the mineralocorticoid receptors antagonist spironolactone in the treatment of CSCR. Criteria of efficacy Endpoint: reduction of subretinal fluid ≥ 40 microns Secondary endpoint: visual acuity gain ≥ 15 EDTRS letters

NCT ID: NCT01151462 Withdrawn - Hearing Loss Clinical Trials

Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.

Start date: August 2010
Phase:
Study type: Observational

The aim of this study is to investigate short and long term consequences from early postnatal HCMV infection transmitted via human milk in very preterm infants (birth weight < 1500 g or gestational age < 32 weeks). These infants are at high risk of early death or survival with chronic disease and neurodevelopmental impairment if infected with HCMV. Infection is a common complication in this group of patients and reported to be the most frequent cause of death after the second week of life. Systemic infection in the newborn period is reported as representing an independent risk factor for survival with neurodevelopmental impairment among very preterm infants.

NCT ID: NCT00508040 Completed - Clinical trials for Cystoid Macular Edema

Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a

BIRDFERON
Start date: September 2007
Phase: Phase 2
Study type: Interventional

Birdshot Retine choroidopathy (BRC) is a sight threatening posterior uveitis. The long term visual outcome has recently be studied showing a legal blindness to 14% at 5 years. Visual acuity is threatened by macular edema (80%), macular atrophy, and choroidal neovascularization.

NCT ID: NCT00372294 Active, not recruiting - Chorioretinitis Clinical Trials

To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

Start date: July 2005
Phase: Phase 3
Study type: Interventional

Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.